Lilly (LLY) Updates on EXPEDITION in Alzheimer's; Slowing Observed in Pooled Analysis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Eli Lilly (LLY) Higher on Alzheimer Drug Hopes, Though Results Fail to Impress Analysts
October 9, 2012 11:39 AM EDTRecent studies of Eli Lilly's (NYSE: LLY) EXPEDITION in patients with mild Alzheimer's showed a statistically significant 34 percent slowing of cognitive decline versus placebo.
Analysts at MKM Partners said while the efficacy of Lilly's alzheimers drug was not overly impressive and longer-term... More
Eli Lilly (LLY) Moves Higher on Large Block Trade
October 9, 2012 9:55 AM EDTEli Lilly & Co. (NYSE: LLY) on th move as a 1.14 million share block trade pushed the stock above $51.55 today.
Overall, Lilly shares are up 1.8 percent Tuesday, following a 5.3 percent run yesterday on new EXPEDITION data.
Average volume for Lilly is about 7.5 million shares.... More
Goldman Sachs Upgrades Eli Lilly (LLY) to Neutral on New "Hope Trade"
October 9, 2012 7:01 AM EDTGoldman Sachs upgraded Eli Lilly (NYSE: LLY) from Sell to Neutral with a price target of $54.00 (from $42.00) saying the Sola data supports optionality trade.
New solanezumab data provides a backbone for the recent "hope trade," the firm notes.
"Our... More
